8-KEarnings & ResultsRegulation FDExhibits & Filings

REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Jan 10, 2022)

Filed January 10, 2022For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on January 10, 2022, to disclose preliminary financial and operational updates provided at the 40th Annual J.P. Morgan Healthcare Conference. The key takeaway for investors is the strong performance of two of its major products. U.S. net product sales for EYLEA® (aflibercept) Injection reached approximately $5.79 billion for the full year 2021, with $1.54 billion in the fourth quarter alone. Furthermore, REGEN-COV® (casirivimab and imdevimab) demonstrated exceptional sales, generating approximately $5.82 billion for the full year 2021, including a significant $2.29 billion in the fourth quarter. These preliminary figures highlight substantial revenue contributions from these key therapies and provide investors with an early look at the company's recent performance ahead of official earnings releases.

Key Highlights

  • 1Regeneron provided preliminary 2021 full-year U.S. net product sales for EYLEA® of approximately $5.79 billion.
  • 2Preliminary fourth quarter 2021 U.S. net product sales for EYLEA® were approximately $1.54 billion.
  • 3Regeneron reported preliminary 2021 full-year U.S. net product sales for REGEN-COV® of approximately $5.82 billion.
  • 4Preliminary fourth quarter 2021 U.S. net product sales for REGEN-COV® reached approximately $2.29 billion.
  • 5The information was presented by Regeneron's CEO and CSO at the 40th Annual J.P. Morgan Healthcare Conference.
  • 6This 8-K filing incorporates information from a presentation furnished as Exhibit 99.1.

Frequently Asked Questions

No, the figures provided in this 8-K are preliminary and unaudited. Investors should refer to Regeneron's official quarterly and annual reports for audited financial statements and comprehensive results.

The sales figures indicate strong market demand and significant revenue generation from these two key products. EYLEA® continues to be a major revenue driver, while REGEN-COV® showed substantial sales, likely influenced by its use in treating COVID-19 during the reporting period.

This 8-K filing does not specify the exact date for the official earnings release. Investors should monitor Regeneron's investor relations website and SEC filings for announcements regarding their upcoming earnings call and detailed financial report.

No, this specific 8-K filing focuses on preliminary results for the full year 2021 and the fourth quarter of 2021. It does not appear to contain forward-looking guidance for 2022.